Karvy Stock Broking has recommended a buy rating on Torrent Pharmaceuticals with a target of Rs 200. The research firm expects the company`s key growth enablers, domestic formulation business and generics business in Brazil, Russia and Europe set to grow the top-line at a CAGR of 15.3% from Rs 13.55 bn in FY08 to Rs 18.02 bn in FY10.
| NIFTY 
